BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year total asset growth rate
5Y CAGR
-29.9%/yr
Long-term compound
Percentile
P82
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.17% |
| Q3 2025 | -2.35% |
| Q2 2025 | -4.76% |
| Q1 2025 | -2.12% |
| Q4 2024 | -0.17% |
| Q3 2024 | 3.99% |
| Q2 2024 | 0.97% |
| Q1 2024 | -9.49% |
| Q4 2023 | -1.14% |
| Q3 2023 | -1.31% |
| Q2 2023 | 3.95% |
| Q1 2023 | -7.32% |
| Q4 2022 | -1.54% |
| Q3 2022 | 9.41% |
| Q2 2022 | -3.26% |
| Q1 2022 | -10.27% |
| Q4 2021 | 121.31% |
| Q3 2021 | -4.15% |
| Q2 2021 | -2.51% |
| Q1 2021 | -15.02% |
| Q4 2020 | 89.94% |
| Q3 2020 | -17.92% |
| Q2 2020 | 57.19% |
| Q1 2020 | -22.07% |
| Q4 2019 | 93.68% |
| Q3 2019 | -22.21% |
| Q2 2019 | -18.26% |
| Q1 2019 | -3.07% |
| Q4 2018 | -12.75% |
| Q3 2018 | 23.17% |
| Q2 2018 | -12.05% |
| Q1 2018 | -12.84% |
| Q4 2017 | -6.91% |
| Q3 2017 | 68.70% |
| Q2 2017 | -12.36% |
| Q1 2017 | 44.15% |
| Q4 2016 | -1.81% |
| Q3 2016 | 11.29% |
| Q2 2016 | -20.09% |
| Q1 2016 | -17.40% |